DISCLAIMER:
Data provided here do by no means exclude the personal physician's
responsibility in performing treatment protocols.
Dosage data have to be cross-checked by reviewing the original
literature. Protocols listet here do not represent "standard" therapy
options. Patients are requested to check with their oncologists prior to
treatment. Treatment protocols are required to be executed by health
care professionals trained and board-certified in medical oncology only.
HINT: Jump BACK to TOP of the list by double-clicking anywhere on the
screen.
CHEMO-/CYTOKINE THERAPY: CYTOTOXIC DRUGS & DRUG COMBINATIONS
FOTEMUSTINE
Fotemustine 100 MG/Mē I.V. days 1 und 8
6 weeks rest period, then continue on day 1 only every 4 - 6 weeks.
DACARBAZINE
Dacarbazine (DTIC) 250 MG/Mē I.V. days 1-5
Repeat on day 29.
TEMOZOLOMIDE
Temozolomide 150 MG/Mē p.o. days 1–5
Repeat on day 29: Temozolomide 200 MG/Mē p.o.in case of absent toxicity.
DACARBAZINE
+ INTERFERON
Dacarbazine (DTIC) 250 MG/Mē I.V. days 1-5
or 850 MG/Mē I.V. day 1
Repeat on day day 29
in addition (optionally): IFN alfa 3 x 10 MIU S.C. days 2-7.
DARTMOUTH
REGIMEN
BCNU 150 MG/Mē I.V. day 1 (every 6 weeks or every second cycle)
Cisplatin 50 MG/Mē I.V. days 1-3 Repeat on day 29
Dacarbazine (DTIC) 220 MG/Mē I.V. days 1-3 Repeat on day 29
Tamoxifen 160 MG/d P.O. days 1-7
Toxicity: Bone marrow depression, anorexia, emesis, nausea,
thromobocyTOPenia, deep vein thrombosis (DVP) possible.
Reference: DelPrete SA, Maurer LH, O’Donnell J, Jackson Forcier R, Le
Marbre: Cancer Treat Rep 68: 1403 - 1405 (1984)
SEQUENTIAL
CHEMOIMMUNOTHERAPY
BCNU 150 MG/Mē I.V. day 1
Cisplatin 25 MG/Mē I.V. days 1-3, days 22-24
Dacarbazine (DTIC) 220 MG/Mē I.V. day 1-3, days 22-24
Tamoxifen 10 MG/d P.O. days 1-42
Interleukin-2 1.5 x 10 MIU/Mē B.I.V. every 8 hours on days 4-8 and 17-21
IFN alfa 6 x 10 MIU/Mē S.C. days 4-8 and 17-21
Toxicity: Bone marrow depression, anorexia, emesis, nausea, fatigue
syndrome, capillary leakage syndrome, thromobocyTOPenia, deep vein
thrombosis (DVP) possible.
Richards JM: Semin Oncol 18, Suppl 7, 91-95 (1991)
SEQUENTIAL
CVD/IL-2/IFN-BIOCHEMOTHERAPY
Cisplatin 20 MG/Mē I.V. days 2-5
Vinblastin 1.6 MG/Mē I.V. days 1-5
Dacarbazine (DTIC) 800 MG/Mē I.V. day 1
Interleukin-2 3 x 10 MIU/Mē C.I.V. 24h days 6-9
IFN alfa-2a 5 x 10 MIU/Mē S.C. days 6-10
Toxic regimen, however >40% responses, >10% complete responses, some of
which long-lasting.
Toxicity: Bone marrow depression, anorexia, emesis, nausea, fatigue
syndrome, capillary leakage syndrome, severe thromobocyTOPenia, deep
vein thrombosis (DVP) possible.
Reference: Legha S, Buzaid AC, Ring S, Bedikian A, Plager C, Eton O,
Papadopoulos N, Benjamin RS: Proc Am Soc Clin Oncol 13: 134 (1994)
ITBCD-PROTOCOL
IFN alfa-2b intra-/perilesionally (skin and soft-tissue mets;
otherwise adjacent to primary tumor location):
3 x 10 MIU days 1-3
5 x 10 MIU days 4-7
10 x 10 MIU I.L./P.L. days 8-14
Tamoxifen 160 MG/d P.O. days 8-14
BCNU (every 2. cycle) 150 MG/Mē I.V. day 15
Cisplatin 25 MG/Mē I.V. days 15-17
Dacarbazine (DTIC) 220 MG/Mē I.V. days 15-17
Repeat on day 29 (without BCNU).
Toxicity: Bone marrow depression, anorexia, emesis, nausea, severe
thromobocyTOPenia, potential deep vein thrombosis (DVP) due to
overlapping effects.
Reference: Voigt H, Classen R, Ramaker J: In: Banzet P, Holland JF,
Khayat D, Weil M (eds): Cancer Treatment Update, Springer 1994, 623-627.
BHD-PROTOCOL
BCNU* 150 MG/Mē I.V. day 1 (*every 2nd cycle only!)
Hydroxyurea 1.500 MG/Mē p.o. day 1–5
DTIC 400 MG/Mē I.V. day 3, 5
Repeat (without BCNU!) on day 29
IL = Interleukin-2, IFN = Interferon alfa 2a/2b, DTIC = Dacarbazine,
BCNU = Carmubris, MIU = Million International Units, I.L. =
Intralesional, P.L. = Perilesional, P.O. = Peroral, C.I.V. = Continuous
Intravenous Infusion, B.I.V. = Intravenous Bolus Injection/Infusion,
I.V. = Intravenously, S.C. = Subcutaneously
|
|
